Pocenbrodib is Pathos’ first clinical-stage asset in its pipeline. "The clinical promise of pocenbrodib, our potential best-in-class CBP/p300 inhibitor, lies not only in its remarkable efficacy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback